Results 81 to 90 of about 5,427 (131)

Correction: Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors. [PDF]

Front Immunol
Alsaafeen BH, Ali BR, Elkord E.
europepmc   +1 more source

Modification-Response Integrated Modules Driven Cyclization-Dependent Prodrug Self-Assembly for Reshaping Pro-Apoptotic Tumor Redox Homeostasis. [PDF]

Exploration (Beijing)
Sun Y, Zuo S, Zang W, Li L, Shi X, Li M, He Z, Sun B, Sun J.   +8 more
europepmc   +1 more source

Human Serum Albumin as a Prodrug Carrier for Tumor Therapy: Mechanisms, Applications, and Future Perspectives. [PDF]

Pharmaceutics
Shang Y, Wang S, Yan Y, Tian E, She L, Ma Z.   +5 more
europepmc   +1 more source

Case Report: Two cases of pathologic complete response after upfront chemoimmunotherapy for initially unresectable gastric cancer. [PDF]

Front Oncol
Smith-Uffen M, Nathan P, Zhang CJ, Leslie K, McDonald L, Cecchini M, Vincent M.   +6 more
europepmc   +1 more source

Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks. [PDF]

Sci Rep
Qin N, Bian Z, Chen J.
europepmc   +1 more source

Polymer-Metal Nanoparticle Hybrid Systems for Targeted Breast Cancer Therapy: Advances and Clinical Translation. [PDF]

Cureus
Mane PA, Mohite A, Datkhile KD, Pathade GR, Sonavale RM.   +4 more
europepmc   +1 more source

Recurrent Metastatic Malignant Wolffian Tumour: A Rare and Aggressive Clinical Course. [PDF]

Cureus
Zhao J, Yeo YC, Boricha YB, Bhutia K, Qi M.   +4 more
europepmc   +1 more source

A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer. [PDF]

Nat Cancer
Wang Z, Li W, Jiang Y, Ma T, Li M, Wu S, Tran TB, Cordova LE, Lin E, Scott AJ, Erdrich J, Schroeder J, Chalasani P, Lu J.   +13 more
europepmc   +1 more source

Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer. [PDF]

Acta Pharm Sin B
Pérez-Herrero E, Fernández-Medarde A, Irache JM.   +2 more
europepmc   +1 more source

The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients. [PDF]

Cancer Res Commun
Brancato L, Gorbaslieva I, Rudenko O, Logghe T, van Zwol E, Boulet G, Van den Bossche L, Van den Bossche J, Peeters M, Chapelle T, Saldien V, Vueghs P, Vandamme T, Dankerlui R, Ysebaert D, Bogers J.   +15 more
europepmc   +1 more source